Besifloxacin demonstrated in vitro inhibitory activity against common and resistant ocular bacterial pathogens1

The ARMOR study found that besifloxacin, the active molecule in BESIVANCE, demonstrated in vitro inhibitory activity against common and resistant ocular bacterial pathogens. This study measured the minimum inhibitory concentration (μg/mL) that inhibits the growth of 90% of indicated isolates (MIC90 ).1

Interested in viewing the pediatric subgroup data from the ARMOR study? Click here.

ARMOR study results of antibiotic activity against ocular pathogens

Table only includes antibiotics that are available in topical ophthalmic products that have a bacterial conjunctivitis indication. Vancomycin was part of the ARMOR study, but is not indicated for bacterial conjunctivitis. The table is not intended to demonstrate clinical efficacy. Clinical significance of these in vitro data has not been established.

*MSSA n=952; MRSA n=543.

MSCoNS n=690; MRCoNS n=641.

S. pneumoniae n=399; P. aeruginosa n=499; H. influenzae n=513.

§Polymyxin B is used in combination with trimethoprim for bacterial conjunctivitis.

NA = Not available

ARMOR Study Limitations1

  • Participating sites in the United States were invited to submit isolates of S. aureus, CoNS, S. pneumoniae, H. influenzae, and P. aeruginosa cultured from eye infections
  • There is potential for sampling bias due to the infrequent practice of culturing bacterial pathogens
  • The application of system breakpoints to define susceptibility to ocular treatments, and thus the applicability to topically applied antibiotics, may not be relevant
  • Because topical antibiotics are rapidly eliminated from tears due to tear turnover, the antibiotic concentration in ocular tissue may not be indicative of the actual concentration effect

REGISTER FOR UPDATES

Get additional information and resources.

Learn about long-lasting tear concentrations

See the tear concentrations that help besifloxacin fight bacterial pathogens.

 
 
Indication

BESIVANCE® (besifloxacin ophthalmic suspension) 0.6% is a quinolone antimicrobial indicated for the treatment of bacterial conjunctivitis caused by susceptible isolates of the following bacteria: Aerococcus viridans*, CDC coryneform group G, Corynebacterium pseudodiphtheriticum*, Corynebacterium striatum*, Haemophilus influenzae, Moraxella catarrhalis*, Moraxella lacunata*, Pseudomonas aeruginosa*, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus hominis*, Staphylococcus lugdunensis*, Staphylococcus warneri*, Streptococcus mitis group, Streptococcus oralis, Streptococcus pneumoniae, Streptococcus salivarius*

*Efficacy for this organism was studied in fewer than 10 infections.

Important Safety Information
  • BESIVANCE is not for injection into the eye.
  • As with other anti-infectives, prolonged use of BESIVANCE may result in overgrowth of non-susceptible organisms, including fungi. If super-infection occurs, discontinue use and institute alternative therapy.
  • Patients should not wear contact lenses if they have signs or symptoms of bacterial conjunctivitis or during the course of therapy with BESIVANCE.
  • The most common adverse event reported in approximately 2% of patients treated with BESIVANCE was conjunctival redness. Other adverse events reported in patients receiving BESIVANCE occurring in approximately 1-2% of patients included: blurred vision, eye pain, eye irritation, eye pruritus and headache.
  • Safety and effectiveness in infants below one year of age have not been established.

Click here for full Prescribing Information for BESIVANCE.

References: 1. Thomas RK, Melton R, and Asbell PA. Antibiotic resistance among ocular pathogens: current trends from the ARMOR surveillance study (2009-2016). Clin. Optom. 2019;11:15-26.

 
Indication

BESIVANCE® (besifloxacin ophthalmic suspension) 0.6% is a quinolone antimicrobial indicated for the treatment of bacterial conjunctivitis caused by susceptible isolates of the following bacteria: Aerococcus viridans*, CDC coryneform group G, Corynebacterium pseudodiphtheriticum*, Corynebacterium striatum*, Haemophilus influenzae, Moraxella catarrhalis*, Moraxella lacunata*, Pseudomonas aeruginosa*, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus hominis*, Staphylococcus lugdunensis*, Staphylococcus warneri*, Streptococcus mitis group, Streptococcus oralis, Streptococcus pneumoniae, Streptococcus salivarius*

*Efficacy for this organism was studied in fewer than 10 infections.

Important Safety Information
  • BESIVANCE is not for injection into the eye.
  • As with other anti-infectives, prolonged use of BESIVANCE may result in overgrowth of non-susceptible organisms, including fungi. If super-infection occurs, discontinue use and institute alternative therapy.
  • Patients should not wear contact lenses if they have signs or symptoms of bacterial conjunctivitis or during the course of therapy with BESIVANCE.
  • The most common adverse event reported in approximately 2% of patients treated with BESIVANCE was conjunctival redness. Other adverse events reported in patients receiving BESIVANCE occurring in approximately 1-2% of patients included: blurred vision, eye pain, eye irritation, eye pruritus and headache.
  • Safety and effectiveness in infants below one year of age have not been established.

Click here for full Prescribing Information for BESIVANCE.

THIS WEBSITE IS INTENDED FOR U.S. HEALTHCARE PROFESSIONALS ONLY.

Please choose an option below: